Biomarkers and trial endpoints

Long COVID research pivots from cataloguing symptoms to testing candidate mechanisms

Six years and thousands of studies have produced leads worth testing, but the researchers doing the work say the missing piece is a reliable disease marker, which is exactly what a trial needs to measure anything.